** Hong Kong shares of InnoCare Pharma 9969.HK jump 11.5% to HK$7.25, highest since November 13, 2024
** Shanghai-listed stock 688428.SS rises 7.1% to 13.68 yuan, highest since December 16, 2024
** China's National Medical Products Administration (NMPA) approves registrational Phase III study of drug used to treat a form of blood cancer
** Hong Kong-listed stock fell 11.2% last year, while Shanghai stock rose 6.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.